In the news

BostonScientific MedSurg EVP Dave Pierce shares his excitement for the future of our Endoscopy and Urology/Pelvic Health businesses, and why he’s proud of how the company has navigated through the uncertainty of the past year.

Boston Scientific has won FDA 510(k) clearance for a single-use bronchoscope designed to eliminate the infection risk associated with reusable devices.

Opinion: Boston Scientific's president of endoscopy writes that government policies have enabled the medtech giant to reinvest profits in multiple areas of innovation. "Patients cannot benefit from bets we don’t make.

A new study using Boston Scientific's EkoSonic endovascular system (EKOS) aims to address current gaps in clinical guidelines for the treatment of pulmonary embolism.

The advent of cardiac resynchronization therapy (CRT) changed the landscape of heart failure management options, but perhaps a third of patients receiving biventricular pacemakers for CRT don't respond to it. The observational study, SMART MSP, demonstrated that CRT with multisite LV pacing (MSP) made responders out of half of patients in whom CRT had failed over the previous 6 months in a prospective trial.

CMS granted a NTAP for single-use duodenoscopes, which applies to Boston Scientific's Exalt Model D single-use duodenoscope, as part of the FY 2022 hospital IPPS. This means that beginning Oct. 1, 2021, CMS will give hospitals additional device reimbursement when single-use duodenoscopes are used for eligible cases in the hospital inpatient setting.

David Knapp, Vice President of Research and Development for Peripheral Interventions at Boston Scientific, joins us to talk about the value of innovation culture, how businesses today go about creating and sustaining an innovative company and embracing the sustainability imperative.

Fueled by billions of its own dollars, the medical technology industry's successes are built on a willingness to invest with a long-term horizon. Some of our bets may never pay off, but our successes have the potential to transform millions of lives.

Boston Scientific has exerted its right to acquire the remaining shares of Farapulse, a company that has developed a pulsed field ablation system for the treatment of cardiac arrhythmias.

Vance Brown has worked in the company's legal department for 20 years. But he's facing new challenges as the GC, including the task of bringing a global workforce back to the office.